Mobile Site ›
Print Friendly View

Test ID: HCCP    
Hereditary Colon Cancer Multi-Gene Panel

Useful For Suggests clinical disorders or settings where the test may be helpful

Providing a comprehensive evaluation for hereditary colon cancer in patients with a personal or family history suggestive of a hereditary colon cancer syndrome

 

Serving as a second-tier test for patients in whom previous targeted gene mutation analyses for specific hereditary colorectal cancer-related genes were negative

 

Establishing a diagnosis of a hereditary colon cancer syndrome in some cases, allowing for targeted cancer surveillance of associated extra-colonic organs known to be at increased risk for cancer

 

Identifying mutations within genes known to be associated with increased risk for colon cancer allowing for predictive testing of at-risk family members

Genetics Test Information Provides information that may help with selection of the correct test or proper submission of the test request

This test includes next-generation sequencing, Sanger sequencing, array comparative genomic hybridization, and multiplex ligation-dependent probe amplification to evaluate for the genes listed on the panel.

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Colorectal cancer occurs in approximately 5% to 6% of individuals in the general population. In rare cases, individuals with a family history of colorectal cancer may be at increased risk for colon and other cancers due to a single-gene predisposition syndrome, known as hereditary colorectal cancer. The 2 most common hereditary colorectal cancer syndromes are Lynch syndrome and familial adenomatous polyposis (FAP). However, there are multiple other genes which are also known to cause to hereditary colorectal cancer or contribute to an increased risk for colorectal cancer. This panel uses next generation sequencing (NGS), array comparative genomic hybridization (aCGH), and other technologies to evaluate for germline mutations in 17 genes known to be associated with an increased risk for colon cancer development. Two of the genes listed, CHEK2 and MLH3, are not associated with a known hereditary cancer syndrome defined by a distinct spectrum of tumors. However, literature suggests that mutations in these genes may confer an increased risk for colon cancer and therefore are predicted to contribute to cancer risk in patients and families.

Gene

Known Association

MLH1

Lynch syndrome

MSH2

Lynch syndrome

MSH6

Lynch syndrome

PMS2

Lynch syndrome

EPCAM

Lynch syndrome

APC

Familial adenomatous polyposis

MYH/MutYH

MYH-associated polyposis

SCG5/GREM1

Hereditary mixed polyposis syndrome

STK11

Peutz-Jeghers syndrome

SMAD4

Juvenile polyposis syndrome

BMPR1A

Juvenile polyposis syndrome

PTEN

PTEN hamartoma tumor syndrome (ie, Cowden syndrome)

CDH1

Hereditary diffuse gastric cancer

AXIN2

Oligodontia-colorectal cancer syndrome

TP53

Li-Fraumeni syndrome

CHEK2

Low-risk gene

MLH3

Low-risk gene

 

Indications for testing include but are not limited to:

-Patients in whom no specific colorectal cancer syndrome is evident but for whom there is a clear familial component

-Patients whose family history is consistent with familial colorectal cancer type X (1)

-Patients with a strong suspicion for a single-gene hereditary colon cancer syndrome based on an autosomal dominant pattern of colon cancer in the family

-Patients with a personal or family history of colonic polyposis

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

An interpretive report will be provided.

Interpretation Provides information to assist in interpretation of the test results

All detected alterations are evaluated according to American College of Medical Genetics and Genomics recommendations.(2) Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Clinical Correlations:

Some individuals who have involvement of 1 or more of the genes on the panel may have a mutation that is not identified by the methods performed (eg, promoter mutations, deep intronic mutations). The absence of a mutation, therefore, does not eliminate the possibility of a hereditary colorectal cancer syndrome or other heritable risk for colon cancer. For predictive testing of asymptomatic individuals, it is important to first document the presence of a gene mutation in an affected family member.

                           

Test results should be interpreted in context of clinical findings, family history, and other laboratory data. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.

 

Technical Limitations:

In some cases, DNA variants of undetermined significance may be identified. Due to the limitations of Next Generation Sequencing, small deletions and insertions greater than 8 nucleotides in length will not be detected by this test. If a diagnosis of one of the syndromes on this panel is still suspected, consider full gene sequencing using traditional Sanger methods. Single or multi-exon deletions as well as whole gene deletions will be detected by array CGH. Rare polymorphisms exist that could lead to false-negative or false-positive results. If results obtained do not match the clinical findings, additional testing should be considered.

 

In addition to disease-related probes, the multiplex ligation-dependent probe amplification technique utilizes probes localized to other chromosomal regions as internal controls. In certain circumstances, these control probes may detect other diseases or conditions for which this test was not specifically intended. Results of the control probes are not normally reported. However, in cases where clinically relevant information is identified, the ordering physician will be informed of the result and provided with recommendations for any appropriate follow-up testing.

 

A previous bone marrow transplant from an allogenic donor will interfere with testing. Call Mayo Medical Laboratories at 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.

 

Evaluation Tools:

Multiple in-silico evaluation tools were used to assist in the interpretation of these results. These tools are updated regularly, therefore changes to these algorithms may result in different predictions for a given alteration. Additionally, the predictability of these tools for the determination of pathogenicity is currently unvalidated.

 

Unless reported or predicted to cause disease, alterations found deep in the intron or alterations that do not result in an amino acid substitution are not reported. These and common polymorphisms identified for this patient are available upon request.

 

Reclassification of Variants-Policy:

All detected alterations are evaluated according to American College of Medical Genetics and Genomics recommendations (2). Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance. At this time, it is not standard practice for the laboratory to systematically review likely deleterious alterations or variants of uncertain significance that are detected and reported. The laboratory encourages health care providers to contact the laboratory at any time to learn how the status of a particular variant may have changed over time.

Clinical Reference Provides recommendations for further in-depth reading of a clinical nature

1. Lindor NM, Rabe K, Petersen GM, et al: Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 2005;293(16):1979-1985

2. Richards CS, Bale S, Bellissimo DB, et al: ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007. Genet Med 2008:10(4):294-300

3. Lindor NM, McMaster ML, Lindor CJ, et al: Concise Handbook of Familial Cancer Susceptibility Syndromes. Second Edition. J Natl Cancer Inst Monogr 2008;(38):1-93

4. Genetics of Colorectal Cancer. Edited by JD Potter, NM Lindor. 2009, New York, Springer Verlag, 2009 pp 213-217

5. Jaeger E, Leedham S, Lewis A, et al: Hereditary mixed polyposis syndrome is caused by a 40-kb upstream duplication that leads to increased and ectopic expression of the BMP antagonist GREM1. Nat Genet 2012;44(6):699-703

6. Ligtenberg MJL, Kuiper RP, Chan TL, et al: Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. Nat Genet 2009;41(1):112-117

7. Lammi L, Arte S, Somer M, et al: Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer. Am J Hum Genet 2004;74:1043-1050

8. Liu HX, Zhou XL, Liu T, et al: The role of hMLH3 in familial colorectal cancer. Cancer Res 2003;63(8):1894-1899

Special Instructions and Forms Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test